2-Substituted estradiol bis-sulfamates, multitargeted antitumor agents: Synthesis, in vitro SAR, protein crystallography, and in vivo activity

Journal of Medicinal Chemistry

Volumn 49, Issue 26, 2006, Pages 7683-7696

  Leese, Mathew P ^a   Leblond, Bertrand ^a   Smith, Andrew ^a   Newman, Simon P ^b   Di Fiore, Anna ^c   De Simone, Giuseppina ^c   Supuran, Claudiu T ^d   Purohit, Atul ^b   Reed, Michael J ^b   Potter, Barry V L ^a  

^a University of Bath   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c CNR   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYLESTRADIOL 3,17 O,O BISULFAMATE; 2 METHOXYESTRADIOL 3,17 O,O BISULFAMATE; CARBONATE DEHYDRATASE II; ESTRADIOL 17 O SULFAMATE; ESTRADIOL 3,17 O,O BISULFAMATE; ESTRADIOL DERIVATIVE; STERYL SULFATASE; UNCLASSIFIED DRUG; ZINC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; BREAST CARCINOMA; CANCER INHIBITION; CONTROLLED STUDY; DRUG BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; LEWIS CARCINOMA; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; BREAST NEOPLASMS; CARBONIC ANHYDRASE II; CARCINOMA, LEWIS LUNG; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; ESTRADIOL; FEMALE; HUMANS; MICE; MICE, NUDE; MODELS, MOLECULAR; NEOVASCULARIZATION, PATHOLOGIC; STERYL-SULFATASE; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONIC ACIDS; SURVIVAL RATE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZINC;

EID: 33845953699     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060705x     Document Type: Article

References (58)

1. Howarth, N. M.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Estrone sulfamates: Potent inhibitors of estrone sulfatase with therapeutic potential. J. Med. Chem. 1994, 37, 219-221.
2. Purohit, A.; Williams, G. J.; Roberts, C. J.; Potter, B. V. L.; Reed, M. J. In vivo inhibition of estrone sulfatase and dehydroepiandrosterone sulfatase by estrone-3-O-sulfamate. Int. J. Cancer 1995, 63, 106-111.
3. Reed, M. J.; Purohit, A.; Newman, S. P.; Potter, B. V. L. Steroid sulfatase: Molecular biology, regulation and inhibition. Endocr. Rev. 2005, 26, 171-202.
4. Stanway, S. J.; Purohit, A.; Woo, L. W. L.; Sufi, S.; Vigushin, D.; Ward, R.; Wilson, R.; Stanczyk, F. Z.; Dobbs, N.; Kulinkaya, E.; Elliott, M.; Potter, B. V. L.; Reed, M. J.; Coombs, R. C. Phase I study of STX64 (667 Coumate) in breast cancer patients: The first study of a steroid sulfatase inhibitor. Clin. Cancer Res. 2006, 12, 1585-1592.
5. Woo, L. W. L.; Purohit, A.; Malini, B.; Reed, M. J.; Potter, B. V. L. Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates. Chem. Biol. 2000, 7, 773-791.
6. Abbate, F.; Winum, J. Y.; Potter, B. V. L.; Casini, A.; Montero, J. L.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase. Bioorg. Med. Chem. Lett. 2004, 14, 231-234.
7. Elger, W.; Schwarz, S.; Hedden, A. M.; Reddersen, G.; Schneider, B. Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J. Steroid Biochem. Mol. Biol. 1995, 55, 395-403.
8. Fotsis, T.; Zhang, Y. M.; Pepper, M. S.; Adlercreutz, H.; Montesano, R.; Nawroth, P. P.; Schweigerer. L. The endogenous estrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumor growth. Nature 1994, 368, 237-239.
9. D'Amato, R. J.; Lin, C. M.; Flynn, E.; Folkman, J.; Hamel, E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3964-3968.
10. Mabjeesh, N. J.; Escuin, D.; LaVallee, T. M.; Pribluda, V. S.; Swartz, G. M.; Johnson, M. S.; Willard, M. T.; Zhong, H.; Simons, J. W.; Giannakakou, P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003, 3, 363-375.
11. Escuin, D.; Kline, E. R.; Giannakakou, P. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1 alpha accumulation and activity by disrupting microtubule function. Cancer Res. 2005, 65, 9021-9028.
12. Cushman, M.; He, H. M.; Katzenellenbogen, J. A.; Lin, C. M.; Hamel, E. Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J. Med. Chem. 1995, 38, 2041-2049.
13. Cushman, M.; He, H. M.; Katzenellenbogen, J. A.; Varma, R. K.; Hamel, E.; Lin, C. M.; Ram, S.; Sachdeva, Y. P. Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerization and cancer cell growth. J. Med. Chem. 1997, 40, 2323-2334.
14. Edsall, A. B.; Mohanakrishnan, A. K.; Yang, D. L.; Fanwick, P. E.; Hamel, E.; Hanson, A. D.; Agoston, G. E.; Cushman, M. Effects of altering the electronics of 2-methoxyestradiol on cell proliferation, on cytotoxicity in human cancer cell cultures, and on tubulin polymerization. J. Med. Chem. 2004, 47, 5126-5139.
15. Cushman, M.; Mohanakrishnan, A. K.; Hollingshead, M.; Hamel, E. The effect of exchanging various substituents at the 2-position of 2-methoxyestradiol on cytotoxicity in human cancer cell cultures and inhibition of tubulin polymerization. J. Med. Chem. 2002, 45, 4748-4754.
16. Rao, P. N.; Cessac, J. W.; Tinley, T. L.; Mooberry, S. L. Synthesis and antimitotic activity of novel 2-methoxyestradiol analogs. Steroids 2002, 67, 1079-1089.
17. Tinley, T. L.; Leal, R. M.; Randall-Hlubek, D. A.; Cessac, J. W.; Wilkens, L. R.; Rao, P. N.; Mooberry, S. L. Novel 2-methoxyestradiol analogues with antitumor activity. Cancer Res. 2003, 63, 1538-1549.
18. Newman, S. P.; Ireson, C. R.; Tutill, H. J.; Day, J. M.; Parsons, M. F. C.; Leese, M. P.; Potter, B. V. L.; Reed, M. J.; Purohit, A. The role of 17β-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer. Cancer Res. 2006, 66, 324-330.
19. Dahut, W. L.; Lakhani, N. J.; Kohn, E. C.; Gulley, J.; Arlen, P. M.; Raggio, M.; Wright, J.; Hussain, M. M.; Kotz, H.; Figg, W. D. A phase I study of 2-methoxyestradiol (2ME2) in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 2003, 2005.
20. Purohit, A.; Vernon, K. A.; Hummelinck, A. E. W.; Woo, L. W. L.; Hejaz, H. A. M.; Potter, B. V. L.; Reed, M. J. The development of A-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity. J. Steroid Biochem. Mol. Biol. 1998, 64, 269-275.
21. Leese, M. P.; Hejaz, H. A. M.; Mahon, M. F.; Newman, S. P.; Purohit, A.; Reed, M.; Potter, B. V. L. A-ring substituted estrogen sulfamates: Potent multi-targeted anti-cancer agents. J. Med. Chem. 2005, 48, 5243-5256.
22. MacCarthy-Morrogh, L.; Townsend, P. A.; Purohit, A.; Hejaz, H. A. M.; Potter, B. V. L.; Reed, M. J.; Packham, G. Differential effects of estrone and estrone-3-O-sulfamate derivatives on mitotic arrest, apoptosis, and microtubule assembly in human breast cancer cells. Cancer Res. 2000, 60, 5441-5450.
23. Newman, S. P.; Leese, M. P.; Purohit, A.; James, D. R. C.; Rennie, C. E.; Potter, B. V. L.; Reed, M. J. Inhibition of in vitro angiogenesis by 2-methoxy- and 2-ethyl-estrogen sulfamates. Int. J. Cancer 2004, 109, 533-540.
24. Purohit, A.; Hejaz, H. A. M.; Walden, L.; MacCarthy-Morrogh, L.; Packham, G.; Potter, B. V. L.; Reed, M. J. The effect of 2-methoxyoestrone-3-O- sulphamate on the growth of breast cancer cells and induced mammary tumours. Int. J. Cancer 2000, 85, 584-589.
25. Leese, M. P.; Leblond, B.; Newman, S. P.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Anti-cancer activities of novel D-ring modified 2-substituted estrogen-3-O-sulfamates. J. Steroid Biochem. Mol. Biol. 2005, 94, 239-251.
26. Schwarz, S.; Thieme, I.; Richter, M.; Undeutsch, B.; Henkel, H.; Elger, W. Synthesis of estrogen sulfamates: Compounds with a novel endocrinological profile. Steroids 1996, 61, 710-717.
27. Okada, M.; Iwashita, S.; Koizumi, N. Efficient general method for sulfamoylation of a hydroxyl group. Tetrahedron Lett. 2000, 41, 7047-7051.
28. Purohit, A.; Williams, G. J.; Howarth, N. M.; Potter, B. V. L.; Reed, M. J. Inactivation of steroid sulfatase by an active site directed inhibitor, estrone-3-O-suIfamate. Biochemistry 1995, 34, 11508-11514.
29. Reed, J. E.; Woo, L. W. L.; Robinson, J. J.; Leblond, B.; Leese, M. P.; Purohit, A.; Reed, M. J.; Potter, B. V. L. 2-Difluoromethyloestrone 3-O-sulphamate, a highly potent steroid sulphatase inhibitor. Biochem. Biophys. Res. Commun. 2004, 317, 169-175.
30. Woo, L. W. L.; Howarth, N. M.; Purohit, A.; Hejaz, H. A. M.; Reed, M. J.; Potter, B. V. L. Steroidal and non-steroidal sulfamates as potent inhibitors of steroid sulfatase. J. Med. Chem. 1998, 41, 1068-1083.
31. Raobaikady, B.; Purohit, A.; Chander, S. K.; Woo, L. W. L.; Leese, M. P.; Potter, B. V. L.; Reed, M. J. Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-methoxyoestradiol-bis-sulphamate. J. Steroid Biochem. Mol. Biol. 2003, 84, 351-358.
32. Boyd, M. R.; Paull, K. D. Some practical consideration and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res. 1995, 34, 91-109.
33. Paull, K. D.; Lin, C. M.; Malspeis, L.; Hamel, E. Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Res. 1992, 52, 3892-3900.
34. For details see: NCI. http://dtp.nci.nih.gov/aa-resources/aa_index.html, 2004, ref type: electronic citation.
35. Hollingshead, M.; Alley, M. C.; Camalier, R. F.; Abbott, B. J.; Mayo, J. G.; Malspeis, L.; Grever, M. R. In vivo cultivation of tumor cells in hollow fibres. Life Sci. 1995, 57, 131-141.
36. Goldin, A.; Venditti, J. M.; Macdonald, J. S.; Muggia, F. M.; Henney, J. E.; Devita, V. T. Current results of the screening program at the division of cancer treatment, National Cancer Institute. Eur. J. Cancer 1981, 17, 129-142.
37. Ireson, C. R.; Chander, S. K.; Purohit, A.; Perera, S.; Newman, S. P.; Parish, D.; Leese, M. P.; Smith, A. C.; Potter, B. V. L.; Reed, M. J. Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol- bis-sulphamate in vivo in rodents. Br. J. Cancer 2004, 90, 932-937.
38. Raobaikady, B.; Reed, M. J.; Leese, M. P.; Potter, B. V. L.; Purohit, A. Inhibition of MDA-MB-231 cell cycle progression and cell proliferation by C-2-substituted oestradiol mono- and bis-3-O-sulphamates. Int. J. Cancer 2005, 117, 150-159.
39. Ravelli, R. B. G.; Gigant, B.; Curmi, P. A.; Jourdain, I.; Lachkar, S.; Sobel. A.; Knossow, M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004, 428, 198-202.
40. Ho, Y. T.; Purohit, A.; Vicker, N.; Newman, S. P.; Robinson, J. J.; Leese, M. P.; Ganeshapillai, D.; Woo, L. W. L.; Potter, B. V. L.; Reed, M. J. Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamates. Biochem. Biophys. Res. Commun. 2003, 305, 909-914.
41. Lloyd, M. D.; Pederick, R. L.; Natesh, R.; Woo, L. W. L.; Purohit, A.; Reed, M. J.; Acharya, K. R.; Potter, B. V. L. Crystal structure of human carbonic anhydrase II at 1.95 Å resolution in complex with 667-coumate, a novel anti-cancer agent. Biochem. J. 2005, 385, 715-720.
42. Lloyd, M. D.; Thiyagarajan, N.; Ho, Y. T.; Woo, L. W. L.; Sutcliffe, O. B.; Purohit, A.; Reed, M. J.; Acharya, K. R.; Potter, B. V. L. First crystal structures of human carbonic anhydrase II in complex with dual aromatase-steroid sulfatase inhibitors. Biochemistry 2005, 44, 6858-6866.
43. Eriksson, A. E.; Jones, T. A.; Liljas, A. Refined structure of human carbonic anhydrase II at 2.0Å resolution. Proteins 1988, 4, 274-282.
44. Recacha, R.; Costanzo, M. J.; Maryanoff, B. E.; Chattopadhyay, D. Crystal structure of human carbonic anhydrase II complexed with an anti-convulsant sugar sulphamate. Biochem. J. 2002, 361, 437-441.
45. Appel, R.; Berger, G. Uber das hydrazidosulfamid (On hydrazidosulfamide). Chem. Ber. 1958, 91, 1339-1341.
46. Woo, L. W. L.; Lightowler, M.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Heteroatom-substituted analogues of the active-site directed inhibitor estra-1,3,5(10)-trien-17-one-3-sulphamate inhibit estrone sulphatase by a different mechanism. J. Steroid Biochem. Mol. Biol. 1996, 57, 79-88.
47. SYBYL 7.1, Tripos Inc., 1699 South Hanley Rd., St. Louis, MO 63144.
48. Jones, G.; Willett, P.; Glen, R. C. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J. Mol. Biol. 1995, 245, 43-53.
49. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
50. Nissink, J. W. M.; Murray, C.; Hartshorn, M.; Verdonk, M. L.; Cole, J. C.; Taylor, R. A new test set for validating predictions of protein-ligand interaction. Proteins 2002, 49, 457-471.
51. Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved protein-ligand docking using GOLD. Proteins 2003, 52, 609-623.
52. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.
53. Otwinowski, Z.; Minor, W. In Processing of X-ray diffraction data collected in oscillation mode; Carter, C. W., Sweet, R. M., Eds.; Methods in Enzymology, Vol. 276: Macromolecular Crystallography Part A; Academic Press: New York, 1997: pp 307-326.
54. Brunger, A. T.; Adams, P. D.; Clore, G. M.; Delano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J. S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography & NMR system: A new software suite for macro-molecular structure determination. Acta Crystallogr., D 1998, 54, 905-921.
55. Jones, T. A.; Zou, J. Y.; Cowan, S. W.; Kjeldgaard, M. Improved methods for building protein models in electron-density maps and the location of errors in these models. Acta Crystallogr., A 1991, 47, 110-119.
56. For details see: http://dtp.nci.nih.gov/branches/btb/pdf/ In_Vivo_Cancer_Models.pdf.
57. Qian, X.; Abul-Hajj, Y. J. Synthesis and biological activity of 17β-substituted estradiol. J. Steroid Biochem. 1988, 657-664.
58. Nambara, T.; Honma, S.; Akiyama, S. Studies on steroid conjugates. III. New syntheses of 2-methoxyestrogens. Chem. Pharm. Bull. 1970, 18, 474-480.